<main class="html-publication" lang="en" role="main">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/department-of-health-and-social-care">
      <span class="gem-c-organisation-logo__name">Department<br>of Health &amp;<br>Social Care</span>
</a>
</div>
        </li>
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link brand__border-color" href="/government/organisations/nhs-commissioning-board">
      <span class="gem-c-organisation-logo__name">NHS England</span>
</a>
</div>
        </li>
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/uk-health-security-agency">
      <span class="gem-c-organisation-logo__name">UK Health<br>Security<br>Agency</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    Appendix C: vaccines reimbursed as part of the NHS influenza vaccination programme for adults 
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 22 April 2022</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-93b6a51b518ff99714a1aa2a7d2162735c155ec3cb073c75fb88b2a332fa83d3.png">
</p>
<p>
  © Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan/appendix-c-vaccines-reimbursed-as-part-of-the-nhs-influenza-vaccination-programme-for-adults
</p>


    </div>
  </div>

  <div class="main-content-container offset-empty-contents-list">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
      <div class="govspeak">
<p>The Joint Committee on Vaccination and Immunisation (<abbr title="Joint Committee on Vaccination and Immunisation">JCVI</abbr>) has reviewed the latest evidence on influenza vaccines and has made <a class="govuk-link" href="https://app.box.com/s/t5ockz9bb6xw6t2mrrzb144njplimfo0/file/863135232161" rel="external">recommendations</a> about which vaccines to offer for the 2022 to 2023 season. The <a class="govuk-link" href="https://www.england.nhs.uk/publication/annual-seasonal-flu-vaccination-programme-and-reimbursement-guidance/" rel="external">letter on 2 March 2022</a> sets out which of the <abbr title="Joint Committee on Vaccination and Immunisation">JCVI</abbr> recommended vaccines will be reimbursed for adults (please see table below).</p>

<table>
  <thead>
    <tr>
      <th scope="col">Those aged 65 years and   over</th>
      <th scope="col">At-risk adults, including pregnant women,   aged 18 to less than 65 years</th>
      <td style="text-align: center"></td>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Reimbursed vaccines</td>
      <td>&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td>
<abbr title="adjuvanted quadrivalent influenza vaccine">aQIV</abbr> / <abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr>
</td>
      <td>
<abbr title="quadrivalent influenza vaccine, cell based">QIVc</abbr> / <abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr>
</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td>
<abbr title="quadrivalent influenza vaccine, cell based">QIVc</abbr> (only where <abbr title="adjuvanted quadrivalent influenza vaccine">aQIV</abbr> or <abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr> is not available)</td>
      <td>
<abbr title="quadrivalent influenza vaccine, egg based">QIVe</abbr> (only where <abbr title="quadrivalent influenza vaccine, cell based">QIVc</abbr> or <abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr> is not available)</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td>Rationale and further information</td>
      <td>&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td>There are 3 vaccines that <abbr title="Joint Committee on Vaccination and Immunisation">JCVI</abbr> advised are equally suitable for use in 2022 to 2023   as they provide the best protection.</td>
      <td>Evidence from recent influenza seasons indicate a clear additional benefit in the use of quadrivalent influenza vaccines in those less than 65   years of age in an at-risk group, compared with trivalent influenza vaccines.  <abbr title="Joint Committee on Vaccination and Immunisation">JCVI</abbr> advises the use of Quadrivalent influenza cell-culture vaccine (<abbr title="quadrivalent influenza vaccine, cell based">QIVc</abbr>) and Quadrivalent Recombinant Influenza Vaccine (<abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr>).</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td>Adjuvanted   quadrivalent inactivated influenza vaccine (<abbr title="adjuvanted quadrivalent influenza vaccine">aQIV</abbr>) <sup role="doc-noteref"><a class="govuk-link" href="#fn:1" rel="footnote">[footnote 1]</a></sup>, High-dose   quadrivalent inactivated influenza vaccine (<abbr title="high dose quadrivalent influenza vaccine">QIV-HD</abbr>) and Quadrivalent   Recombinant Influenza Vaccine (<abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr>). However, <abbr title="high dose quadrivalent influenza vaccine">QIV-HD</abbr> is not currently   available in the UK market.</td>
      <td>
<abbr title="Joint Committee on Vaccination and Immunisation">JCVI</abbr> supports a preference for   <abbr title="quadrivalent influenza vaccine, cell based">QIVc</abbr> and <abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr> over <abbr title="quadrivalent influenza vaccine, egg based">QIVe</abbr> in this cohort, however the <abbr title="quadrivalent influenza vaccine, egg based">QIVe</abbr> can be considered if   other options are not available. NHS England and NHS Improvement (<abbr title="NHS England and NHS Improvement">NHSEI</abbr>)   advises that <abbr title="quadrivalent influenza vaccine, cell based">QIVc</abbr> and <abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr> should be prioritised for this group for the 2022   to 2023 seasonal influenza vaccination programme.</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
    <tr>
      <td>The   quadrivalent influenza cell-culture vaccine (<abbr title="quadrivalent influenza vaccine, cell based">QIVc</abbr>) is considered an   acceptable alternative and is suitable for use in this age group if <abbr title="adjuvanted quadrivalent influenza vaccine">aQIV</abbr>,   <abbr title="high dose quadrivalent influenza vaccine">QIV-HD</abbr> or <abbr title="recombinant quadrivalent influenza vaccine">QIVr</abbr> are not available.</td>
      <td>&nbsp;</td>
      <td style="text-align: center">&nbsp;</td>
    </tr>
  </tbody>
</table>

<p>Contractual requirements for all commissioned NHS influenza vaccination providers will state that to receive payment for influenza vaccination and reimbursement of influenza vaccine they will need to use the specific influenza vaccines recommended in this aforementioned <abbr title="NHS England and NHS Improvement">NHSEI</abbr> guidance.</p>

<p>Please note, it is not anticipated that any stock will be centrally procured by the Department of Health and Social Care for the 2022 to 2023 season and, therefore, we strongly urge providers to order sufficient volumes of vaccine to serve their eligible populations.</p>

<p>Influenza vaccines generally start to be distributed from manufacturers from September each year. However, vaccine manufacture involves complex biological processes. There is always the possibility that initial batches of vaccine may be subject to delay, or that fewer doses than planned may be available initially. It is recommended that orders are placed with more than one manufacturer in case of supplier delays or difficulties in the manufacture or delivery of the vaccine. Providers should remain flexible when scheduling vaccination sessions and be prepared to reschedule if necessary. Providers should ensure that reassuring message are given to patients who may request a vaccine before supply is available and be encouraged to rebook or find an alternative provider with sufficient supply.</p>

<p>Some influenza vaccines are restricted for use in particular age groups. The Summary of Product Characteristics (SmPC) for individual products should always be referred to when ordering vaccines for particular patients. The <a class="govuk-link" href="https://www.gov.uk/government/publications/influenza-vaccines-marketed-in-the-uk">vaccines that are available for the 2022 to 2023 influenza immunisation programme</a> are available on GOV.UK (including details of ovalbumin content).</p>

<p>The <abbr title="UK Health Security Agency">UKHSA</abbr> <a class="govuk-link" href="https://www.gov.uk/government/publications/flu-vaccines-for-the-current-season">influenza vaccines poster for 2022 to 2023</a> will be available later in the year.</p>

<p>Influenza vaccines for eligible children are centrally procured by <abbr title="UK Health Security Agency">UKHSA</abbr> and are supplied free of charge to providers via ImmForm. These vaccines will NOT be reimbursed as part of the NHS Seasonal Influenza Vaccination Programme (see <a class="govuk-link" href="https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan/appendix-d-influenza-vaccines-for-the-childrens-programme">Appendix D</a> for further details).</p>

<div class="footnotes" role="doc-endnotes">
  <ol>
    <li role="doc-endnote">
      <p>As in previous years, <abbr title="adjuvanted quadrivalent influenza vaccine">aQIV</abbr> may be offered ‘off-label’ to those who become 65 years of age before 31 March 2023.&nbsp;<a aria-label="go to where this is referenced" class="govuk-link" href="#fnref:1" role="doc-backlink">↩</a></p>
    </li>
  </ol>
</div>
</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" focusable="false" height="17" viewBox="0 0 13 17" width="13" xmlns="http://www.w3.org/2000/svg">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>